Skip to main content
Full access
Letters to the Editor
Published Online: 1 September 2008

Aripiprazole Effects on Psychosis and Chorea in a Patient With Huntington’s Disease

To the Editor: Huntington’s disease is an autosomal dominant inherited disorder characterized by a triad of motor, cognitive, and psychopathological symptoms (1) . Currently, the only treatment options available for the disease are symptomatic. Aripiprazole is a novel antipsychotic drug that possesses the pharmacological characteristics of a partial agonist of the dopamine D 2 and serotonin 5-HT 1A receptors and antagonist of the 5-HT 2A receptor. We report the use of aripiprazole in the treatment of psychotic symptoms in a patient with Huntington’s disease whose diagnosis was confirmed by DNA analysis.
“Mr. A” was a 47-year-old single man who suffered from frequent falls as a result of an unsteady gait and involuntary movements over the past 4 years. He was diagnosed with Huntington’s disease but refused treatment. Approximately 2 years before his current evaluation, he began to demonstrate impairment in activities of daily living and talking to himself. He also developed irritability, persecutory delusions, and intermittent violent behavior toward his family. Obvious choreiform movements and unsteady gait were noted when the patient was admitted to the acute psychiatric ward. His family history was positive for Huntington’s disease, with an elder brother who was bedridden and a sister who died from the disease. His medical history showed that he had only received irregular treatment with risperidone orally (1–3 mg per day) during a 2-week period. Aripiprazole (10 mg per day) was started and increased to 20 mg per day. Subsequently, his personal hygiene and psychotic symptoms were significantly improved within 2 weeks. His choreiform movement decreased significantly, and his gait became stable, enabling him to walk smoothly without assistance. Before treatment with aripiprazole, his score on the chorea sub-item of the Unified Huntington’s Disease Rating Scale was 18. After treatment, his score decreased to 8.
The pathophysiology of involuntary movements among individuals with Huntington’s disease may be related to the dopamine system (2), although the genetic defect with aberrant cytosine-adenine-guanine trinucleotide repeats in the ITI5 gene on the short arm of chromosome 4 implicates dysfunction of the glutamate system. Interestingly, in an animal model it has been shown that a dopamine partial agonist could partially restore social withdrawal behavior in hypoglutamatergic mice (3), which implicates the interaction of dopamine and glutamate systems. Aripiprazole, which has unique dopamine receptor activity compared with other atypical antipsychotics, may similarly have unique effects in treating the psychotic symptoms of Huntington’s disease. Future controlled studies may help provide an understanding of the role of various neuroleptics in the treatment of psychotic symptoms associated with Huntington’s disease.

Footnotes

The authors report no competing interests.
This letter (doi: 10.1176/appi.ajp.2008.08040503) was accepted for publication in May 2008.
Reprints are not available; however, Letters to the Editor can be downloaded at http://ajp.psychiatryonline.org.

References

1.
Walker FO: Huntington’s disease. Lancet 2007; 369:218–228
2.
Charvin D, Vanhoutte P, Pages C, Borrelli E, Caboche J: Unraveling a role for dopamine in Huntington’s disease: the dual role of reactive oxygen species and D 2 receptor stimulation. Proc Natl Acad Sci U S A 2005; 102:12218–12223
3.
Rung JP, Carlsson A, Markinhuhta KR, Carlsson ML: The dopaminergic stabilizers (−)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog Neuropsychopharmacology Biol Psychiatry 2005; 29:833–839

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1207 - 1208
PubMed: 18765501

History

Published online: 1 September 2008
Published in print: September, 2008

Authors

Details

YUAN-HWA CHOU, M.D., Ph.D.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share